225ac-psma
Peptideexperimental
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2020 (NCT04225910)
Timeline
Indications
Mechanism of action
- Glutamate carboxypeptidase IIINHIBITOR
FOLH1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 225-Actinium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06881823 | Phase 1/Phase 2 (Phase 2) | Jun 29, 2026 | Novartis |
| NCT06909825 | Phase 2 | Feb 26, 2025 | Fusion Pharma LLC |
| NCT07135102 | Phase 1 | Oct 14, 2024 | Shandong University |
| NCT06217822 | Phase 1 | Mar 7, 2024 | Bayer |
| NCT06402331 | Phase 2/Phase 3 (Phase 3) | Mar 5, 2024 | Fusion Pharma LLC |
| NCT05983198 | Phase 1/Phase 2 (Phase 2) | Nov 7, 2023 | Novartis |
| NCT05219500 | Phase 2 | Dec 16, 2021 | Excel Diagnostics and Nuclear Oncology Center |
| NCT04225910 | Early Phase 1 (Phase 1) | Jan 1, 2020 | Jiao Tong University |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fusion Pharma LLC | For profit | 2 | 2 | 2 | 2024 |
| Novartis | For profit | 2 | 2 | 1 | 2023 |
| Bayer | For profit | 1 | 1 | 1 | 2024 |
| Excel Diagnostics and Nuclear Oncology Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Shandong University | Academic/Hospital | 1 | 1 | 1 | 2024 |
6 organizations
Page 1 / 1